Facility & Equipment Details
Description
The Facility for Experimental Radiopharmaceutical Manufacturing (FERM) is a component of the Stony Brook University PET Research Core. FERM is dedicated to the development and production of cGMP grade radiopharmaceuticals to support preclinical and clinical PET imaging at Stony Brook University.
The laboratory is directed by Professor Wenchao Qu, PhD.
The PET Research Core is directed by Professor Mark Slifstein PhD.
PET Research at Stony Brook University is directed by Professor Ramin Parsey, MD PhD, Della Pietra Family Chair of Biomedical Imaging.
Who We Are
FERM is a comprehensive core for the synthesis and characterization of PET radiopharmaceuticals. We have fully trained staff and validated equipment for the synthesis of cGMP 18F radiolabeled pharmaceuticals.
Over 500 18F radiopharmaceuticals have been characterized in vivo and over 200 of these used in humans as probes of biological systems and have applications in oncology, cardiology, neurology, psychiatry and drug development (see NIH MICAD database at http://www.ncbi.nlm.nih.gov/books/NBK5330/).
PET radiopharmaceuticals are generally administered in pharmacologically inactive amounts and are non-toxic. PET tracers are designed to be specific for a defined transport or receptor system and hence, enable the probing of basic biochemical processes in real time.
Services provided
-Full cGMP manufacturing of clinical grade radiopharmaceutical in compliance with FDA and USP guidelines
-Assistance in obtaining local (RDRC) or federal (IND) approval
-Supports both preclinical and clinical PET imaging studies
The laboratory is directed by Professor Wenchao Qu, PhD.
The PET Research Core is directed by Professor Mark Slifstein PhD.
PET Research at Stony Brook University is directed by Professor Ramin Parsey, MD PhD, Della Pietra Family Chair of Biomedical Imaging.
Who We Are
FERM is a comprehensive core for the synthesis and characterization of PET radiopharmaceuticals. We have fully trained staff and validated equipment for the synthesis of cGMP 18F radiolabeled pharmaceuticals.
Over 500 18F radiopharmaceuticals have been characterized in vivo and over 200 of these used in humans as probes of biological systems and have applications in oncology, cardiology, neurology, psychiatry and drug development (see NIH MICAD database at http://www.ncbi.nlm.nih.gov/books/NBK5330/).
PET radiopharmaceuticals are generally administered in pharmacologically inactive amounts and are non-toxic. PET tracers are designed to be specific for a defined transport or receptor system and hence, enable the probing of basic biochemical processes in real time.
Services provided
-Full cGMP manufacturing of clinical grade radiopharmaceutical in compliance with FDA and USP guidelines
-Assistance in obtaining local (RDRC) or federal (IND) approval
-Supports both preclinical and clinical PET imaging studies
Existing radiopharmaceuticals include:
[18F]fallypride (dopamine D2/3)
[18F]FEPPA (TSPO)
[18F]VAT (vesicularacetylcholine transporter)
[18F]T807 (Tau ligand for neurodegeneration)
[18F]LY2459989 (κ-opioid receptor antagonist)
[18F]MK-9470 (CB1R inverse agonist)
[18F]Florbetaben (Amyloid ligand for neurodegeneration)
Fingerprint
Explore the research areas in which this equipment has been used. These labels are generated based on the related outputs. Together they form a unique fingerprint.